EF Hutton analyst Tony Butler initiated coverage of Atreca with a Buy rating and $10 price target. Atreca has developed a unique platform to discover and develop novel antibody-based immuno-therapeutics for solid tumors, Butler tells investors in a research note. The anlayst says the company’s lead product candidate ATRC-101, a monoclonal antibody, is in Phase 1 clinical development in a variety of solid cancers targeting an intracellular ribonucleoprotein complex in tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCEL: